简介:AIM:TocomprehensivelyevaluatethepotentialassociationofCOL1A1polymorphismswithhighmyopiabyasystematicreviewandMeta-analysis.METHODS:AllassociationstudiesonCOL1A1andhighmyopiareporteduptoJune10,2014inPubMed,Embase,WebofScience,andtheChineseBiomedicalDatabasewereretrieved.Oddsratios(ORs)and95%confidenceintervals(95%CIs)wereanalyzedforsinglenucleotidepolymorphisms(SNPs)usingfixed-andrandom-effectsmodelsaccordingtobetween-studyheterogeneity.PublicationbiasanalyseswereconductedbyEgger’stest.RESULTS:Atotaloffourstudiesfromreportedpaperswereincludedinthisanalysis.TheMeta-analysesforCOL1A1rs2075555,composedof2304highmyopiapatientsand2272controls,failedtodetectanysignificantassociationwithhighmyopia.Atotalof971casesand649controlsweretestedforCOL1A1rs2269336.TheassociationofCOL1A1rs2269336withhighmyopiawasobservedinrecessivemodel(CCvsCG+GG,P=0.03)andinheterozygousmodel(CGvsGG,P=0.04),butnotinothermodels.CONCLUSION:ThisMeta-analysisshowsthatCOL1A1rs2269336(CCvsCG+GG)affectsindividualsusceptibilitytohighmyopia,whereasthereisnoassociationdetectedbetweenSNPsrs2075555andhighmyopia.Giventhelimitedsamplesize,furtherinvestigationsincludingmoreethnicgroupsarerequiredtovalidatetheassociation.
简介:目的对照观察和评价弥可保和腺苷钴胺片治疗外伤性视神经挫伤的临床疗效,评估弥可保的治疗有效性和优越性。方法将37例外伤性视神经挫伤患者随机分为二组,分别用弥可保和腺苷钴胺片治疗,比较两组间视力改善及视神经萎缩发生情况。结果弥可保治疗组视力改善有效率为63.15%,腺苷钴胺片对照组视力改善有效率为27.78%;两组差别具有统计学意义(P〈0.05);弥可保治疗组视神经萎缩发生率为46.15%,腺苷钴胺片对照组视神经萎缩发生率为72.22%,两组差别具有统计学意义(P〈0.05)。结论弥可保对外伤性视神经挫伤的治疗有明显的临床疗效,是一种疗效肯定的治疗外伤性视神经挫伤的药物,其对视功能的恢复优于腺苷钴胺片。
简介:患者,男,51岁,2004年8月因“左眼颈椎手术后视物不见2个月”至本院就诊。左眼:视力无光感,眼球各方向运动中度受限,屈光介质透明,瞳孔散大,直接对光(-),间接对光反应迟钝,视网膜灰黄色,血管变细,视乳头苍白,脉络膜背景污秽色,眼底无出血渗出。右眼:无阳性体征。现病史:患者2004年6月因“无骨折脱位性颈脊髓损伤并不全瘫”在当地医院行颈椎手术。麻醉方式:静脉复合麻醉,俯卧,颈部过伸位。手术持续时间:4小时40分。术前患者双眼视力均正常,苏醒后即左眼视物完全不见,右眼正常,当地医院眼科检查治疗情况不详。我院诊断:左眼部缺血综合征。